Shionogi President Expects Strong Growth On Synergy Effect With Sciele
This article was originally published in PharmAsia News
Executive Summary
Shionogi President Isao Teshirogi expects a strong growth after 2009 when a full synergy effect from acquiring U.S. company Sciele Pharma will take place. Teshirogi expressed the view at a Nov. 4 press briefing to announce interim results. The company has established a U.S. sales network through the ¥155 billion deal, and it also started operations in U.S. and European markets. Regarding U.S. clinic trials for Shionogi's obesity drug S-2367, Teshirogi commented that the results could be announced early next year. Teshirogi also touched upon recent rapid appreciation of yen, he said it is unlikely that the currency appreciation will help reduce research and development expenses in the U.S. (Click here for more - Japanese language